Ameliorating antipsychotic-induced weight gain by betahistine: mechanisms and clinical implications
The SUSTAIN and SURPASS trial serieswhich evaluated these medications for diabetes and weight lossdocumented cycle changes as a potential side effect, though severe cases were uncommon
Acknowledgements The National Natural Science Foundation of China (82073144, J.W.), the Health Commission of Zhejiang Province (JBZX-202004, J.W.), the Huadong Medicine Joint Funds of the Zhejiang Provincial Natural Science Foundation of China (LHDMD22H310005, J.W.)
These observations were supported by our mutagenesis studies, where mutations R299 ECL2 A in GLP-1R, R289 ECL2 A in GIPR and I194 2.67b K in GCGR caused variable decreases in retatrutide potency (by 3.7-fold, 4.6-fold and 36.0-fold, respectively), while S297 ECL2 A in GCGR slightly increased retatrutide potency